Showing 1611-1620 of 2152 results for "".
- Gyroscope Therapeutics Initiates Phase 2 Program Evaluating its Investigational Gene Therapy for Dry AMDhttps://modernod.com/news/gyroscope-therapeutics-initiates-phase-2-program-evaluating-its-investigational-gene-therapy-for-dry-amd/2478157/Gyroscope Therapeutics announced the initiation of its phase 2 program evaluating its investigational gene therapy, GT005, for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). GT005 is a one-time AAV-based gene therapy that is delivered under the r
- Oxurion Appoints Grace Chang, MD, PhD, as Chief Medical Officerhttps://modernod.com/news/oxurion-appoints-grace-chang-md-phd-as-chief-medical-officer/2478109/Oxurion NV announced the appointment of Grace Chang, MD, PhD, as the company’s Chief Medical Officer, effective August 1, 2020. Dr. Chang is a board-certified ophthalmologist and practicing vitreoretinal surgeon with deep expertise in ophthalmic drug research and development. She will be r
- Alcon Survey Shows More Screen Time Causing Consumer Concern About Eye Health, Increasing Symptoms of Dry Eyehttps://modernod.com/news/alcon-survey-shows-more-screen-time-causing-consumer-concern-about-eye-health-increasing-symptoms-of-dry-eye/2478054/Alcon announced the results of a new survey, conducted by research firm Ipsos among 1,005 US adults, that uncover the impact the COVID-19 pandemic is having on consumers’ screen time and how that impacts their perceptions on eye health. Key findings include: Nearly 80% of Americans r
- GenSight Biologics Reports Sustained Efficacy and Safety Among LHON Patients 3 Years After Lumevoq Treatmenthttps://modernod.com/news/gensight-biologics-reports-sustained-efficacy-and-safety-among-lhon-patients-3-years-after-lumevoq-treatment/2477972/GenSight Biologics reported that Leber Hereditary Optical Neuropathy (LHON) subjects treated with Lumevoq experienced sustained efficacy and safety 3 years after a single injection with the gene therapy. These findings come from CLIN06, the long-term follow-up study to which participants in the R
- AsclepiX Therapeutics Announces $35 Million Series A Financinghttps://modernod.com/news/asclepix-therapeutics-announces-35-million-series-a-financing/2477929/AsclepiX Therapeutics announced that it has closed a $35 million Series A financing to fund phase 1/2a clinical trials of AXT107, the company’s lead investigational drug, for the treatment of diabetic macular edema (DME), wet age-related macular degeneration (AMD) and macular edema secondary to r
- Inovio Hints at Positive Early Phase 1 Safety Data for COVID-19 Vaccine INO-4800https://modernod.com/news/inovio-hints-at-positive-early-phase-1-safety-data-for-covid-19-vaccine-ino-4800/2477810/Inovio Pharmaceuticals suggested that preliminary safety data from an ongoing phase 1 trial indicates that its experimental COVID-19 DNA vaccine candidate INO-4800 appears to be safe in humans. “We are already seeing safety data and it has been benign,” commented R&D head K
- The Allergan Foundation Doubles its COVID-19 Response Donations to $4.0 Millionhttps://modernod.com/news/the-allergan-foundation-doubles-its-covid-19-response-donations-to-4-0-million/2477733/Allergan announced that The Allergan Foundation has fast-tracked another $2 million dollars in charitable grants for community organizations responding to the COVID-19 pandemic. The new grants double The Allergan Foundation’s total COVID-19 donations to date, r
- Nicox to Present NCX 470 Phase 2 Results at Glaucoma 360 New Horizons Forumhttps://modernod.com/news/nicox-to-present-ncx-470-phase-2-results-at-glaucoma-360-new-horizons-forum/2477281/Nicox SA today announced that Tomas Navratil, PhD, Executive Vice President, Head of R&D of Nicox group, and General Manager of Nicox Ophthalmics, Inc, will present results from the NCX 470 Dolomites phase 2 clinical trial in the session “New Horizons in Pharmaceuticals” at the Glaucoma 360 N
- Vision Health Initiative Named a Mutual of America 2019 Community Partnership Award Winnerhttps://modernod.com/news/vision-health-initiative-named-a-mutual-of-america-2019-community-partnership-award-winner/2477094/Mutual of America announced that “Seeing the Future: Vision Health Initiative” was named a Merit Finalist award recipient of its 2019 Community Partnership Award competition. Seeing the Future: Vision Health Initiative was launched by Care For the Homeless (CFH) in 2016 after r
- Lineage Cell Therapeutics Presents Encouraging Data on Vision Restoration Programhttps://modernod.com/news/lineage-cell-therapeutics-presents-encouraging-data-on-vision-restoration-program/2477041/Lineage Cell Therapeutics announced today that Igor Nasonkin, PhD, Principal Investigator and Director of R&D, served as a co-Chair of the Neural Differentiation, Transplantation, and Regeneration Nanosymposium, in addition to presenting data on the company’s Vision Restoration Program at Neu